Dianthus raises $1B, reports positive Phase 2 gMG data, achieves early CIDP milestone

Filed May 5, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~1 min read

Key Changes

• high

  Raised $1.0 billion in two public offerings (Sept 2025: $288M, March 2026: $719M), extending cash runway from mid-2027 to 2030 and funding Phase 3 trials through potential commercial launch.

  MD&A: Capital Raises verify on EDGAR →
• high

  Phase 2 gMG trial met primary endpoints with statistically significant improvements at week 1 and week 13; FDA end-of-Phase 2 meeting completed, Phase 3 registrational trial expected mid-2026.

  MD&A: Clinical Programs verify on EDGAR →
• high

  Phase 3 CIDP trial achieved early GO decision with 20+ responders using fewer patients than planned, allowing dose optimization and 47% reduction in planned enrollment (480 to 256 patients in Part A).

  MD&A: CAPTIVATE Trial verify on EDGAR →